医学
内科学
急性冠脉综合征
心脏病学
不稳定型心绞痛
血运重建
再狭窄
狼牙棒
支架
阿司匹林
心肌梗塞
经皮冠状动脉介入治疗
作者
Nicola Locuratolo,Pietro Scicchitano,Ettore Antoncecchi,P Basso,V. M. Bonfantino,F. Brescia,Francesco Carrata,Giulia Martino,Raffaella Landriscina,Saverio Lanzone,A. Di Lillo,Francesco Massari,Sergio Musci,Vincenzo Davide Palumbo,Claudio Paolillo,David Rutigliano,Sergio Rutigliano,Lucia Sublimi Saponetti,Giuseppe Scalera,Teresa Spadafina,Elisabetta Squiccimarro,Francesco Tota,Pasquale Caldarola
出处
期刊:PubMed
日期:2022-01-01
卷期号:23 (1): 63-74
被引量:3
摘要
Patients who suffered from acute coronary syndrome (ACS) need a tight follow-up in order to optimize therapy and prevent adverse events. The aim of the PONTE-SCA Puglia program was to evaluate the impact of an integrated management of patients between hospital and local territorial outpatient facilities on adherence and outcome of patients discharged after ACS event.This was a prospective, longitudinal, cohort study which enrolled patients who suffered ACS and/or coronary revascularization in a Hub hospital of ASL Bari. Patients underwent clinical and laboratory evaluation at 30 days, 3 months, 6 months, and 1 year after the index event. The following endpoints were considered: all-cause mortality, ACS recurrence/cardiac ischemia/angina, restenosis/intrastent thrombosis, stroke/transient ischemic attack, heart failure, all-cause bleeding. We evaluated persistence on therapies and the percentage of patients who attained therapeutic goals.A total of 2476 patients (mean age 67.2 ± 12.0 years, 77.4% male) were enrolled. At 1-year follow-up, 99.5% of patients (p<0.05) were on statin therapy, 16.1% (p<0.01) on ezetimibe, and 9.9% (p<0.01) on proprotein convertase subtilisin/kexin type 9 inhibitors. All-cause mortality was 3.1% at 1-year follow-up, whereas recurrence of ACS/cardiac ischemia/angina and restenosis/stent thrombosis were 3% and 1.3%, respectively. The prevalence of all bleeding complications was 2.2%.The PONTE-SCA Puglia program allowed to implement a dedicated taking in charge of patients after an ACS/coronary revascularization event, to manage a dedicated follow-up route for them, to ameliorate persistence on recommended therapies, and to keep lower the incidence of major adverse cardiovascular events and bleedings.